Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Magdum, C. S.
- Screening of Some Indigenous Plants for Their Antipyretic Activity
Abstract Views :228 |
PDF Views:0
Authors
Affiliations
1 Appasaheb Birnale College of Pharmacy, South Shivajinagar, Sangli-416 416, IN
1 Appasaheb Birnale College of Pharmacy, South Shivajinagar, Sangli-416 416, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 1, No 3 (2009), Pagination: 143-144Abstract
In the present study, aqueous extract of leaves of Capparis zeylanica Linn, Annona reticulata Linn and Clerodendron phlomidis Linn were given at a dose of 200mg/kg, 400mg/kg (p.o.).
The antipyretic activity was done after inducing hyperpyrexia by injecting subcutaneously 20% aqueous suspension of Brewer's yeast in rats. Rats developing 0.5° C-1° C or more rises in rectal temperature 18 h after injection were taken for study.
The results proved that the aqueous extract of leaves of Clerodendron phlomidis Linn and Annona reticulata Linn has significant antipyretic activity and were compared with paracetamol (150 mg/kg body weight, p.o.), a standard antipyretic agent. Aqueous extract of leaves of Capparis zeylanica Linn has not reduced elevated fever in experimental rats.
Keywords
Capparis zeylanica Linn, Clerodendron phlomides Linn, Annona reticulata Linn, Antipyretic Activity.
References
- Shastri BM. The wealth of India. A dictionary of Indian raw materials & industrial products. CSIR, New Delhi. 1995.
- Kritikar KR. and Basu BD. Indian medicinal plants. Vol.II. Lalit mohan Basu Prakashan, Allahabad. 1933.
- Nadkarni KM. Indian Materia medica, Popular Prakashan, Bombay. 1982.
- Loux JJ, Depalma PD, Yankell SL. Antipyretic testing of aspirin in rats, Toxicol Appl Pharmacol. 1972; 2: 672-5.
- Murugesan, T.,et al. Evaluation of Antipyretic potential of Jussiaea suffruticosa Linn. Extract in rat. Phytomedicine. 2000; 7(3): 231.
- Subrata K. et. al. Antipyretic activity of Eupatorium adenophorum leaf extract, Indian J. Nat. Prod. 2005; 21(1): 16-17.
- Kulkarni SK. Handbook of Experimental Pharmacology. Vallabh Prakashan, II Edition Delhi. 1993.
- Gerhard HV and Wolf HV. Drug Discovery and Evaluation of Pharmacological assays Springer-Verla, New York. 1997; 1st Edn.: PP.390-418.
- Bolton S and Bon C. Pharmaceutical statistics, Marcel Dekker Publication, Blacksburg. 2004; 4st edition: P.437.
- In Vitro Anthelmintic Activity of Medicinal Plants against Pheretima posthuma
Abstract Views :445 |
PDF Views:2
Authors
Affiliations
1 Appasaheb Birnale College of Pharmacy, South Shivaji Nagar, Sangli - Miraj Road, Sangli. 416416, IN
2 Rajarambapu College of Pharmacy, Kasegaon, Sangli, IN
1 Appasaheb Birnale College of Pharmacy, South Shivaji Nagar, Sangli - Miraj Road, Sangli. 416416, IN
2 Rajarambapu College of Pharmacy, Kasegaon, Sangli, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 3, No 3 (2011), Pagination: 112-114Abstract
In this study, in vitro activity of were conducted to determine the possible anthelmintic activity of different solvent extracts like aqueous extract of leaves of cajanus cajan Linn, methanolic extract of leaves of vitex negundo Linn, Ethanolic extract of bark of Euphorbia tirucalli Linn and ethyl acetate extract of leaves of synadiium grantii Linn, methanolic extract of leaves of Euphorbia nerrifolia Linn against Indian worm Pheretima posthuma. With regard to effect of extract of Euphorbia tirucalli Linn, Euphorbia nerrifolia Linn, cajanus cajan Linn showed significant action on earthworm, vitex negundo Linn showed moderate activity. All the extracts were found not only to paralyse (vermifuse) but also death (vermicidal) except ethyl acetate extract of synadiumm graantii.Keywords
Anthelminitic Activity, Pheretima posthuma, Euphorbia nerrifolia Linn. Euphorbia tirucalli Linn, Synadiium grantii Linn, cajanus cajan Linn, vitex Negundo Linn.References
- Tagboto S., Townson S., Antiparasitic properties of medicinal and other naturally occurring products, Adv Parasitol, , 2001, 50, 199-295.
- Tadessae Eguale, Mirutse Giday, In-vitro anthelmintic activity of three medicinal plants against Haemonchus contortus. International journal of green pharmacy, 2009, 29-34.
- Duke, J.A., "Handbook of legumes of world economic importance", Plenum Press, New York, 1981.
- Rashik, A.M., A. Shukla, G.K. Patnaik, B.N. Dhawan and D.K Kulshrestha, Wound healing activity of latex of Euphorbia neriifolia Linn. Indian J. Pharmacol., 1996, 28(2): 107-109.
- Lanthers MC, Fleurentin J, Dorfman P, Mortier F, Pelt JM. Analgesis, antipyretic and anti- inflammatory properties of Euphorbia hirta. Planta Med, 1991; 57(3):225-231.
- Kirtikar, KR.; Basu, BD., Indian medicinal plants, Vol 3, 1975. pp 2204
- Nair CK, Mohenan N. Medicinal plants in India with special reference to Ayurveda. NAG Publisher, Delhi, India 1998.
- Telang RS, Chatterjee S, Varshneya C. Studies on analgesic and antiinflammatory activities of Vitex negundo Linn. Indian J Pharmacol 1999; 31: 363–366.
- Jana U, Chattopadhyay RN, Shaw BP. Preliminary studies on anti-inflammatory activity of Zingiber officinale , Vitex negundo Linn and Tinospora Cordifolia (willd) miers in albinorats. Indian J Pharmacol 1999; 31: 232–233.
- Ravishankar B, Bhaskaran NR, Sasikala CK. Pharmacological evaluation of Vitex negundo (Nirgundi) leaves. Bull Med Ethno Bot Res 1985; VI (1): 72–92.
- Gupta M, Mazumder UK, Bhawal SR. CNS activity of Vitexnegundo Linn in mice. Indian J Exp Biol 1999; 37; 143–146.
- Avadhoot Y, Rana AC. Hepatoprotective effect of Vitex negundo against carbon tetrachloride induced liver damage.Arch Pharm Res 1991; 14(1): 96–98.
- Nair AM and Saraf MN. Inhibition of antigen and compound 48/80 induced contraction of guinea pig trachea by ethanolic extract of the leaves of Vitex negundo Linn. Indian J Pharmacol 1995; 27: 230– 233.
- Kuvar SD and Bapat UC medicinal plant used by kokani tribals of nasik district Maharashtra to cure cuts and wounds. Indian journal of traditional knowledge VOL.9(1) , 2010, pp,144-115.
- Uma Shankar Sharma,In vitro anthelmintic activity of Murraya koenigii Linn leaves extract. International Journal of Pharma and Bio Sciences Vol.1 (3) 2010 pg no. 1-4.
- Drug used in Inflammatory Bowel Disease (IBD) - Brief Review
Abstract Views :263 |
PDF Views:0
Authors
Affiliations
1 Rajarambapu College of Pharmacy, Kasegaon, Tal.-Walva, Dist.-Sangli - 415 404, IN
1 Rajarambapu College of Pharmacy, Kasegaon, Tal.-Walva, Dist.-Sangli - 415 404, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 6, No 3 (2014), Pagination: 153-161Abstract
Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn's disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including drugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. Drug delivery to the appropriate site(s) along the gastrointestinal tract also has been a major challenge, and second-generation agents have been developed with improved drug delivery, increased efficacy, and decreased side effect The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the, symptoms, diagnosis and current treatments for inflammatory bowel disease.Keywords
Inflammatory Bowel Disease (IBD), 5-Aminosalicylates, Corticosteroids, Infliximab, Herbal Drugs, Symptoms, Diagnosis.References
- Longstreth GF. Definition and classification of irritable bowel syndrome: current consensus and controversies. Gastroenterol. Clin. North Am. 2005; 34: 173-87.
- Drossman DA. Introduction. The Rome Foundation and Rome III. Neurogastroenterol. Motil. 2007; 19: 783-6.
- WHO. International Statistical Classification of Diseases and Related Health Problems, 10th edn. Geneva, Switzerland: World Health Organization, 2007.
- Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ 1978; 2 (6138): 653-4.
- Brandt LJ, Bjorkman D, Fennerty MB et al. Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol. 2002; 97 (11 Suppl.): S7-26.
- Drossman DA, Douglas A, eds. Rome III: The Functional Gastrointestinal Disorder, 3rd edn.
- McClean, VA, USA: Degnon Associates, 2006. 7 Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. Dig. Dis. Sci. 2002; 47: 225-35.
- Talley NJ, Zinsmeister AR, Melton LJ 3rd. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am. J. Epidemiol. 1995; 142: 76-83.
- Cash BD, Chey WD. Diagnosis of irritable bowel syndrome. Gastroenterol. Clin. North Am. 2005; 34: 205-20.
- Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol. Clin. North Am. 2005; 34: 247-55.
- Palsson OS, Drossman DA. Psychiatric and psychological dysfunction in irritable bowel syndrome and the role of psychological treatments. Gastroenterol. Clin. North Am. 2005; 34: 281-303.
- Cash BD, Chey WD. Irritable bowel syndrome-an evidence based approach to diagnosis. Aliment. Pharmacol. Ther. 2004; 19: 1235-45.
- Park JM, Choi MG, Kim YS et al. Quality of life of patients with irritable bowel syndrome in Korea. Qual. Life. Res. 2009; 18: 435-46.
- Katsinelos P, Lazaraki G, Kountouras J et al. Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. Eur. J. Gastroenterol. Hepatol. 2009; 21: 183-9.
- Tan YM, Goh KL, Muhidayah R, Ooi CL, Salem O. Prevalence of irritable bowel syndrome in young adult Malaysians: a survey among medical students. J. Gastroenterol. Hepatol. 2003; 18: 1412-16.
- Hillila MT, Farkkila MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment. Pharmacol. Ther. 2004; 20: 339-45.
- Bommelaer G, Dorval E, Denis P et al. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol. Clin. Biol. 2002; 26: 1118-23.
- World Gastroenterology Organization, 2009 WGO Global Guideline IBD4
- Barnes PJ, Karin M: Nuclear factor-_B. A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 1997, 336, 1066-1071.
- Prantera C, Cottone M, Pallone F: Mesalamine in the treatment of mild to moderate active Crohn's ileitis, results of a randomised multicenter trial. Gastroenterology, 1999, 116, 521-52.
- Camma C, Giunta M, Rosselli M, Cottone M: Mesalamine in the maintenance treatment of Crohn's disease, A meta-analysis adjusted for confounding variables. Gastroenterology, 1997, 113, 1465-1473.
- Wahl C, Liptay S, Adler G, Schmid RM: Sulfasalazine, a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest, 1998, 101, 1163-1174.
- Meyers S, Sachar DB: Medical therapy of Crohn's disease. In: Inflammatory Bowel Disease. 4th edn., Eds. Kersnar JB, Shorter RG, Williams and Wilkins, Baltimore, 1995, 695-714.
- Aberra FN, Lewis JD, Hass D, Rombeau J, Osborne B, Lichtenstein G: Corticosteroids and immunomodulators, postoperative infectious complication risk in inflammatory bowel disease. Gastroenterology, 2003, 125, 320-327.
- Bello C, Goldstein F, Thornton JJ: Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastroenterol, 1991, 86, 460-466.
- Faubion WA Jr, Loftus EV, Harmsen WS, Zinmeister AR, Sandborn WJ: The natural history of corticosteroid therapy for inflammatory bowel disease, a population based study. Gastroenterology, 2001, 121, 255-260.
- Vakil N, Sparberg M: Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology, 1989, 96, 62-67.
- Greenberg GR, Feagan BR, Martin F, Sutherland L, Thomson A,Williams N, Nilsson L, Persson T: Oral budesonide for active Crohn's disease. New Eng J Med, 1994, 331, 836-841.
- Hofer KN: Oral budesonide in management of Crohn's disease. Ann Pharmacother, 2003, 37, 1457-1464.
- Aberra FN, Lewis JD, Hass D, Rombeau J, Osborne B, Lichtenstein G: Corticosteroids and immunomodulators, postoperative infectious complication risk in inflammatory bowel disease. Gastroenterology, 2003, 125, 320-327.
- Fernandes-Banares F, Hinojoso J, Sanchez-Lombrana JL: Randomised clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Am J Gastroenterol, 1999, 2, 427-433.
- Sandborn WJ: A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis, 1995, 1, 48-63.
- Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present D, Braakman T, DeWoody K et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor - for Crohn's disease. New Eng J Med, 1997, 337, 1029-1035.
- Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med, 2007, 357, 228-238.
- Watt K, Christofi N, Young R. The detection of antibacterial actions of whole herb tinctures using luminescent Escherichia coli. Phytother Res 2007; 21: 1193-1199.
- Yoshikawa M, Morikawa T, Oominami H, Matsuda H. Absolute stereo structures of olibanumols A, B, C, H, I, and J from olibanum, gum-resin of Boswellia carterii, and inhibitors of nitric oxide production in lipopolysaccharide-activated mouse peritonea macrophages. Chem Pharm Bull (Tokyo) 2009; 57: 957-964
- Chevrier MR, Ryan AE, Lee DY, Zhongze M, Wu-Yan Z, Via CS. Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro. Clin Diagn Lab Immunol 2005; 12: 575-580
- Camarda L, Dayton T, Di Stefano V, Pitonzo R, Schillaci D. Chemical composition and antimicrobial activity of some oleogum resin essential oils from Boswellia spp. (Burseraceae). Ann Chim 2007; 97: 837-844.
- Moghtader M, Mansouri I, Salari H, Farahmand A. Chemical composition and antimicrobial activity of the essential oil of bunium persicum boiss. Seed. Iran J Med Aromat Plants Spring 2009; 25: 20-28.
- Shahsavari N, Barzegar M, Sahari MA, Naghdibadi H. Antioxidant activity and chemical characterization of essential oil of Bunium persicum. Plant Foods Hum Nutr 2008; 63: 183-188.
- Kumar VP, Chauhan NS, Padh H, Rajani M. Search for antibacterial and antifungal agents from selected Indian medicinal plants. J Ethnopharmacol 2006; 107: 182-188.
- Francis JA, Raja SN, Nair MG. Bioactive terpenoids and guggulusteroids from Commiphora mukul gum resin of potential anti-inflammatory interest. Chem Biodivers 2004; 1: 1842-1853.
- Saeed MA, Sabir AW. Antibacterial activities of some constituents from oleo-gum-resin of Commiphora mukul. Fitoterapia 2004; 75: 204-208.
- Preparation of Novel Biocompatible Honey Hydrogel with Turmaric and Aloe vera
Abstract Views :272 |
PDF Views:6
Authors
Affiliations
1 Rajarambapu College of Pharmacy, Kasegaon. Tal-Walwa, Dist Sangli, Maharashtra, IN
1 Rajarambapu College of Pharmacy, Kasegaon. Tal-Walwa, Dist Sangli, Maharashtra, IN